Bacterial Extracellular Vesicles Deliver exRNA for Autoimmune Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases like psoriasis, atopic dermatitis, Alzheimer's, Polycystic ovarian disorder (PCOD), and Chronic obstructive pulmonary disease (COPD) often provide only symptomatic relief and are challenging due to long-term modalities and high costs, with a need for more effective anti-inflammatory compositions that can downregulate inflammatory cytokines and transcription factors.
Innovation Solution
Development of oral and topical anti-inflammatory compositions comprising extracellular ribonucleic acid (exRNA) encapsulated in extracellular vesicles derived from biofilm-associated extra polymeric substances, which downregulate inflammatory genes by inhibiting specific mRNA targets through antisense/ribozymal cleavage, thereby reducing hyper-inflammatory responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard therapies (topical corticosteroids, vitamin D analogues, retinoids, calcineurin inhibitors) are used for treating autoimmune diseases, then symptomatic relief is provided, but treatment duration is long-term and compliance is difficult
Solution Approach 1:
The patent uses bacterial extracellular vesicles (EVs) as intermediary carriers to deliver anti-inflammatory compounds (exRNA, miRNA, siRNA, plasmid DNA) directly to target cells. These EVs act as natural mediators that facilitate drug delivery and enhance therapeutic efficacy, allowing for reduced treatment duration while maintaining reliability of symptomatic relief in autoimmune diseases like psoriasis, atopic dermatitis, and COPD
Solution Approach 2:
The invention creates composite therapeutic compositions combining bacterial extracellular vesicles with various anti-inflammatory nucleic acid compounds (exRNA, miRNA, siRNA, plasmid DNA). This composite approach integrates the delivery capability of EVs with the therapeutic action of nucleic acids, enabling more effective and shorter-duration treatment compared to conventional monotherapies
2Reliability
If standard therapies are used for autoimmune diseases, then some symptom relief is achieved, but the cost of therapy is high
Solution Approach 1:
The patent employs bacterial extracellular vesicles, which can be produced through simple fermentation processes using common bacteria like E. coli. These EVs serve as cost-effective, disposable delivery vehicles that eliminate the need for expensive conventional drug formulations, significantly reducing therapy costs while maintaining reliable symptom relief in autoimmune conditions
3Object-affected harmful factors
If current anti-inflammatory compositions are used, then inflammatory cytokines are suppressed, but the compositions do not effectively downregulate inflammatory genes
Solution Approach 1:
The patent replaces conventional mechanical/protein-based anti-inflammatory approaches with nucleic acid-based mechanisms (exRNA, miRNA, siRNA, plasmid DNA) that directly target and downregulate inflammatory genes at the molecular level. This substitution of mechanism enables effective gene downregulation rather than merely suppressing cytokine activity, providing more reliable and fundamental treatment of inflammation in autoimmune diseases
Solution Approach 2:
Bacterial extracellular vesicles serve as intermediaries that deliver nucleic acid compounds directly into target cells, enabling the nucleic acids to access the cellular machinery needed for gene downregulation. This intermediary delivery system overcomes cellular barriers and ensures effective intracellular delivery of therapeutic nucleic acids, achieving reliable gene downregulation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions effectively downregulate pro-inflammatory cytokines and genes, such as IL-17, IL-23, IL-6, TNF-α, and TGF-β, leading to significant alleviation of symptoms in autoimmune disease models, including psoriasis, atopic dermatitis, Alzheimer's, and COPD, with potential for scalable industrial production at a lower cost.
Implementation Method 1
downregulate inflammatory genes by inhibiting specific mRNA targets through antisense/ribozymal cleavage
Data Source
AI summary
The present invention relates to an anti-inflammatory composition and also a method of obtaining the same. The anti-inflammatory composition of the present invention is capable of downregulating the inflammatory genes and comprises an extracellular ribonucleic acid (exRNA) encapsulated in an extracellular vesicle (EV) and other suitable excipients wherein both the extracellular ribonucleic acid (exRNA) and extracellular vesicle (EV) are derived from extra polymeric substances (EPS) of gram-positive non-pathogenic bacteria.